Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation Forum
January 04, 2018 08:05 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Streetwise Reports Examines Promising 'Hot' Alzheimer's Market for Biotech with 'Novel' Drug Candidate
November 23, 2017 08:45 ET
|
Streetwise Reports Llc
SAN FRANCISCO, Nov. 23, 2017 (GLOBE NEWSWIRE) -- André Uddin, an analyst with Mackie Research Capital Corp., summarized the quarterly financial results and anticipated catalysts for this Alzheimer's...
Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference
November 08, 2017 08:12 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Cognition Therapeutics to Present Results of CT1812 Phase 1b/2a Clinical Study as Late Breakers at CTAD Meeting on November 2nd and 4th
October 30, 2017 08:12 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Cognition Therapeutics Receives Fast Track Designation from U.S. FDA for First-in-Class Alzheimer’s Candidate, CT1812
October 16, 2017 08:00 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, PA, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Function of Cognition Therapeutics’ Neurological Drug Screening Platform Presented at American Chemical Society National Meeting
August 23, 2017 09:45 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, Aug. 23, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Cognition Therapeutics Reports Drug-Drug Interaction Results for CT1812, a Disease-Modifying Alzheimer’s Disease Candidate
July 19, 2017 04:35 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, July 19, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative small molecule therapeutics for the...
Cognition Therapeutics CEO Kenneth I. Moch Presenting at BioCentury Future Leaders Conference
April 03, 2017 08:00 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, April 03, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...